States why the suspension ended: the MHLW Advisory Committee 'confirmed that there were no particular concerns regarding the safety of the vaccines' and that efficacy outweighed risks; MHLW decided in November 2021 to resume proactive recommendation from April 2022, with a catch-up program for the missed cohorts (April 2022 – March 2025). First-dose rates jumped 53% in April 2022 but remained far below WHO targets.
In April 2022, the Japanese government resumed proactive recommendations for routine HPV vaccination after an 8-year suspension and initiated a catch-up vaccination programme.
States why the suspension ended: the MHLW Advisory Committee 'confirmed that there were no particular concerns regarding the safety of the vaccines' and that efficacy outweighed risks; MHLW decided in November 2021 to resume proactive recommendation from April 2022, with a catch-up program for the missed cohorts (April 2022 – March 2025). First-dose rates jumped 53% in April 2022 but remained far below WHO targets.